Our Mission
Quintessence Biosciences is working to improve the lives of cancer patients by developing new drugs based on EVade Ribonuclease technologies.
Spotlight
Lead Candidate, QBI-139
A Phase I trial of QBI-139 in cancer patients
with solid tumors is ongoing at the University of Wisconsin
Comprehensive Cancer Center (UWCCC)
in Madison and the The University of Texas M. D. Anderson Cancer Center in Houston, Texas.
Informtion about the trial can be found at www.clinicaltrials.gov
(Clinical Trials.gov Identifier: NCT00818831).
Potential enrollees can contact the UWCCC Cancer
Connect (800-622-8922; 608-262-5223; uwccc@uwccc.wisc.edu) or the M.D. Anderson Cancer Center (askMDAnderson at 1-877-MDA-6789; 713-792-1160) for
information. Quintessence Biosciences
will not directly enroll patients. |
Latest News
1.13.2010 Quintessence
Biosciences Announces Expansion of Cancer Clinical Trial for QBI-139 (PDF)
Quintessence Biosciences, Inc. announced today the expansion of the Phase 1 clinical trial of its drug candidate, QBI-139, in patients with late-stage solid tumors. The study will be available through The University of Texas M. D. Anderson Cancer Center in Houston, Texas.
9.03.2009 Phase
II SBIR Grant Will Fund Development of EVade™ Ribonucleases
at Quintessence Biosciences, Inc. (PDF)
Quintessence Biosciences, Inc. today announced the receipt of
a Phase 2 Small Business Innovation Research (SBIR) grant from
the National Cancer Institute to support the development of
next generation drugs based on the EVade™ Ribonuclease
technology.
3.26.2009
Patients Now Enrolling in Phase I Human Trial for
Quintessence Biosciences Cancer Drug, QBI-139 (PDF)
Quintessence Biosciences' presentation, Anti-cancer activity
of human ribonuclease conjugates with enhanced pharmacokinetic
profiles, provides data for conjugates made from the Company's
lead candidate QBI-139.
|
